Marie-Andrée Forget

Marie-Andrée Forget

Auto-generated profile, based on publicly available information

Marie-Andrée Forget

CTMC, 2130 West Holcombe Blvd, Houston TX 77030

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ASAislyn Schalck
Aislyn Schalck
DSDonastas Sakellariou-Thompson
Donastas Sakellariou-Thompson
MFMarie-Andrée Forget
Marie-Andrée Forget
ESEmi Sei
Emi Sei
THTara G. Hughes
Tara G. Hughes
CBChantale Bernatchez
Chantale Bernatchez
Pancreatic ductal adenocarcinoma (PDAC) has few effective treatments. Immunotherapy, an attractive alternative strategy, remains challenging with the lack of knowledge on the tumor-infiltrating lymphocyte (TIL) landscape in PDAC. To generate a reference of T-cell subpopulations, we profiled 80,000 T cells from 57 PDAC samples, 22 uninvolved/normal samples, and cultured TIL using single-cell transcriptomic and T-cell receptor analysis. These data revealed 20 cell states and heterogeneous distributions of TIL populations. The CD8+ TIL contained a putative transitional GZMK+ population based on T-cell receptor clonotype sharing, and cell-state trajectory analysis showed similarity to a GZMB+PRF1+ cytotoxic and a CXCL13+ dysfunctional population. Statistical analysis suggested that certain TIL states, such as dysfunctional and inhibitory populations, often occurred together. Finally, analysis of cultured TIL revealed that high-frequency clones from effector populations were preferentially expanded. These data provide a framework for understanding the PDAC TIL landscape for future TIL use in immunotherapy for PDAC. Significance: To improve the efficacy of immunotherapy in PDAC, there is a great need to understand the PDAC TIL landscape. This study represents a reference of PDAC TIL subpopulations and their relationships and provides a foundation upon which to base future immunotherapeutic efforts. This article is highlighted in the In This Issue feature, p. 2221

23 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
IMIsabelle Le Mercier
Isabelle Le Mercier
DMDavid Monteiro
David Monteiro
KHKatarina Halpin-Veszeleiova
Katarina Halpin-Veszeleiova
KWKarrie Wong
Karrie Wong
ADAnne Dodson
Anne Dodson
MBMicah J. Benson
Micah J. Benson
The solid tumor microenvironment inhibits the functionality of tumor infiltrating T cells recognizing cognate tumor antigen, driving their differentiation towards terminal exhaustion. Interventions are sought to enhance the anti-tumor functionality of tumor-reactive T cells for clinical benefit. The functional genome regulating CD8 + T cell function against solid tumors was mapped by performing genome-wide, focused, and combination in vivo CRISPR/Cas9 screens using OT1 and PMEL TCR transgenic T cells in B16-OVA, MC38-gp100 and EG7-OVA syngeneic tumor models. The ability of the top single hits and combinations, which include Regnase-1 and SOCS1, to enhance CD8 + T cell anti-tumor function was evaluated in the OT1/B16-OVA model with large and established tumors, the disseminated PMEL/B16F10 tumor model, and in a novel murine TIL syngeneic model. The impact of Regnase-1 and SOCS1 single and dual-inactivation on the differentiation of exhausted CD8 + T cell subsets and on long-term persistent memory following tumor clearance was evaluated in OT1 CD8 + T cells in the B16-OVA model. The impact of single and dual-inactivation of Regnase-1 and SOCS1 on the anti-tumor function of experimental human T cell therapeutics was characterized in CRISPR/Cas9-engineered human TIL derived in vitro and in mesothelin-targeting CAR-Ts in vivo. NF-κB and cytokine signaling were identified as the top pathways regulating CD8 + T cell anti-tumor function, with Regnase-1 and Suppressor of Cytokine Signaling 1 (SOCS1) the top single and combination edits regulating the accumulation of tumor-specific TCR transgenic CD8 + T cells in syngeneic tumor models. Dual-inactivation of Regnase-1 and SOCS1 cooperated through non-redundant mechanisms to strongly expand intermediate (Tex int ) and effector (Tex eff ) exhausted CD8 + T cells within lymphoid tissues and tumor, with CD8 + T cells rewired to display an enhanced effector state and suppressed expression of TOX. Dual-edited persistent T effector memory cells (T em ) were formed following tumor clearance. Lastly, Regnase-1 and SOCS1 inactivation enhanced human Tumor Infiltrating Lymphocyte (TIL) and chimeric antigen receptor T cells (CAR-T) therapy functionality. Collectively, this study systematically mapped pathways regulating CD8 + T cell anti-tumor functionality, with Regnase-1 and SOCS1 dual-inactivation found to maximize anti-tumor function through non-redundant mechanisms.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Jason RoszikJason Roszik
Jason Roszik
YQYong Qin
Yong Qin
SESuhendan Ekmekcioglu
Suhendan Ekmekcioglu
MFMarie-Andree Forget
Marie-Andree Forget
PHPatrick Hwu
Patrick Hwu
AJAmir A. Jazaeri
Amir A. Jazaeri
5528 Background: Human papillomaviruses (HPVs) play a major role in development of cervical cancer, and HPV oncoproteins are being targeted by immunotherapies. Although these treatments show promising results in the clinic, many patients do not benefit or the durability is limited. Methods: To explore the landscape of neoantigens in cervix cancer, we predicted all possible mutated neopeptides using exome and RNA sequencing data of a large number of tumors in two independent data sets (n = 194 and 79), and analyzed whether mutation and neoantigen load correlate with expression of genes involved in antigen presentation, infiltrating immune cell type markers, and HPV oncoprotein-associated genes. Normal tissue expression analyses were also performed using data from the Genotype-Tissue Expression project (n = 8,555). Results: We found that potentially immunogenic and targetable neoantigens can be predicted for almost all cervix tumors, including recurrent neoantigens from mutations of known oncogenic driver genes (KRAS G12D, MAPK1 E322K, PIK3CA E545K, PIK3CA E542K, ERBB2 S310F, and ERBB3 V104M). Furthermore, we found that expression of HPV-associated “master regulator” genes is associated with mutation, neoantigen, and HPV load, and also with expression of several important markers in the immune microenvironment. Notably, the OVOL1 master regulator positively correlated with mutation and neoantigen load, and also with PD-L1 and TGFB1 expressions. Furthermore, ENO1 over-expression in cervical cancer was associated with high HPV load, and ENO1 level also positively correlated with PD-L1 and TGFB1 expressions, suggesting that it may be a potential target in cervical cancer. Conclusions: For most of the cervix tumors we report predicted neoantigens, and we also identified recurrent neopeptides derived from mutations in known oncogenes. We have also identified statistically significant associations between neoantigen availability, antigen presentation, cytotoxic T-cell function, suppressive mechanisms, and expression of HPV master regulators to help guide immunotherapies of cervical cancer.

3 April 2023
Verified
Other
Open access
SKShelly Kalaora
Shelly Kalaora
YWYochai Wolf
Yochai Wolf
Tali FefermanTali Feferman
Tali Feferman
EBEilon Barnea
Eilon Barnea
EGErez Greenstein
Erez Greenstein
YSYardena Samuels
Yardena Samuels
Supplementary Tables 1, 2, 4, 5, 8, 10, 13, 14, 15


3 April 2023
Verified
Other
Open access
SKShelly Kalaora
Shelly Kalaora
YWYochai Wolf
Yochai Wolf
Tali FefermanTali Feferman
Tali Feferman
EBEilon Barnea
Eilon Barnea
EGErez Greenstein
Erez Greenstein
YSYardena Samuels
Yardena Samuels
In vitro killing assay movies. Co-culture of 12T melanoma cells with irrelevant 108TILs